WO2005081613A3 - Pharmaceutical compositions of peptides secreted by the venom glands of snakes - Google Patents

Pharmaceutical compositions of peptides secreted by the venom glands of snakes

Info

Publication number
WO2005081613A3
WO2005081613A3 PCT/BR2005/000015 BR2005000015W WO2005081613A3 WO 2005081613 A3 WO2005081613 A3 WO 2005081613A3 BR 2005000015 W BR2005000015 W BR 2005000015W WO 2005081613 A3 WO2005081613 A3 WO 2005081613A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
snakes
venom glands
peptides secreted
evasins
Prior art date
Application number
PCT/BR2005/000015
Other languages
French (fr)
Other versions
WO2005081613A2 (en
Inventor
Mirian Akemi Furuie Hayashi
Antonio Carlos Martins Camargo
Alexander Henning Ulrich
Ruben Dario Sinisterra Millan
Robson Augusto Souza Do Santos
Danielle Alves Ianzer
Raphael Dos Reis Marioni
Carlos Alberto Da Silva
Original Assignee
Biolab Sanus Farmaceutica Ltda
Fundacao De Amparo A Pesquisa
Mirian Akemi Furuie Hayashi
Antonio Carlos Martins Camargo
Alexander Henning Ulrich
Ruben Dario Sinisterra Millan
Robson Augusto Souza Do Santos
Danielle Alves Ianzer
Raphael Dos Reis Marioni
Carlos Alberto Da Silva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmaceutica Ltda, Fundacao De Amparo A Pesquisa, Mirian Akemi Furuie Hayashi, Antonio Carlos Martins Camargo, Alexander Henning Ulrich, Ruben Dario Sinisterra Millan, Robson Augusto Souza Do Santos, Danielle Alves Ianzer, Raphael Dos Reis Marioni, Carlos Alberto Da Silva filed Critical Biolab Sanus Farmaceutica Ltda
Publication of WO2005081613A2 publication Critical patent/WO2005081613A2/en
Publication of WO2005081613A3 publication Critical patent/WO2005081613A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A61K35/583—Snakes; Lizards, e.g. chameleons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention refers to the employment of pharmaceutical compositions of snake venom glands secreted peptides, particularly from Bothrops jararaca, EVASINS, and analogous and derivatives compounds, and associated products, as modulating agents of the acetylcholine receptors. The pharmaceutical compositions of EVASINS are characterized by the ability to prevent the binding of the cocaine to the acetylcholine receptors.
PCT/BR2005/000015 2004-02-11 2005-02-04 Pharmaceutical compositions of peptides secreted by the venom glands of snakes WO2005081613A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0400192-3 2004-02-11
BR0400192-3A BRPI0400192A (en) 2004-02-11 2004-02-11 Pharmaceutical compositions of peptides secreted by snake venom glands, particularly bothrops jararaca, evasins, their analogues, derivatives and associated products for use as acetylcholine receptor modulating agents

Publications (2)

Publication Number Publication Date
WO2005081613A2 WO2005081613A2 (en) 2005-09-09
WO2005081613A3 true WO2005081613A3 (en) 2005-10-13

Family

ID=34891708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2005/000015 WO2005081613A2 (en) 2004-02-11 2005-02-04 Pharmaceutical compositions of peptides secreted by the venom glands of snakes

Country Status (2)

Country Link
BR (1) BRPI0400192A (en)
WO (1) WO2005081613A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698754A1 (en) * 2007-09-11 2009-03-19 Dorian Bevec Use of a peptide as a therapeutic agent
CN108830883B (en) * 2018-06-05 2022-04-01 成都信息工程大学 Visual attention SAR image target detection method based on super-pixel structure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819831A (en) * 1969-06-30 1974-06-25 Squibb & Sons Inc Angiotensin converting enzyme inhibitor-fractionated snake venom
WO2002074782A2 (en) * 2001-03-19 2002-09-26 Biolab Sanus Farmacêutica Ltda. Isolation and purification procedure of vasopeptidase peptide inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819831A (en) * 1969-06-30 1974-06-25 Squibb & Sons Inc Angiotensin converting enzyme inhibitor-fractionated snake venom
WO2002074782A2 (en) * 2001-03-19 2002-09-26 Biolab Sanus Farmacêutica Ltda. Isolation and purification procedure of vasopeptidase peptide inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH., vol. 36, no. 5, 2003, pages 617 - 624 *
COMP BIOCHEM PHYSIOL C., vol. 101, no. 2, 1992, pages 197 - 201 *
DATABASE MEDLINE [online] BORJA-OLIVEIRA C.R. ET AL: "The pharmacological effect of Bothrops neuwiedii pauloensis (jararaca-pintada) snake venom on avian neuromuscular transmission.", Database accession no. (NLM12715081) *
DATABASE MEDLINE [online] COGO J.C. ET AL: "An unusual presynaptic action of Bothrops insularis snake venom mediated by phospholipase A2 fraction.", Database accession no. (NLM9723831) *
DATABASE MEDLINE [online] YAMANOUYE N. ET AL: "Effects of catecholamines on the isolated aorta of the snake Bothrops jararaca.", Database accession no. (NLM1354090) *
JOURNAL OF THE INTERNATIONAL SOCIETY ON TOXICOLOGY., vol. 36, no. 10, 1998, pages 1323 - 1332 *

Also Published As

Publication number Publication date
BRPI0400192A (en) 2005-10-04
WO2005081613A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2007079139A3 (en) Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2001044272A3 (en) Daptomycin analogs as antibacterial agents
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2006069719A3 (en) Lyophilization of virosomes
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
NO20092470L (en) Substituted diazepan compounds as orexin receptor antagonists
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2007009109A3 (en) Antiviral compounds
WO2007089557A3 (en) Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
WO2004080377A3 (en) Kcnq channel modulating compounds and their pharmaceutical use
WO2006105035A3 (en) Muscarinic modulators
WO2006023852A3 (en) Modulators of muscarinic receptors
WO2005009387A3 (en) Azepine derivatives as pharmaceutical agents
WO2006058294A3 (en) Modulators of muscarinic receptors
WO2007056366A3 (en) Compounds and compositions as ppar modulators
WO2007062338A3 (en) Solid formulations
WO2005075467A3 (en) Crystalline forms of zolmitriptan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase